ACE2 and COVID-19: Upon validation of the ACE2-RBD multiplex inhibition assay (Supplemental Table 2), we detected inhibition of ACE2 binding activity in 34 out of 35 COVID-19–positive samples that showed SARS-CoV-2 neutralizing activity in the microneutralization assay, resulting in a sensitivity of 97.14%.